Smartlens

Smartlens is a clinical-stage company with its portfolio of innovative technologies for diagnosing and treating glaucoma, a chronic eye disease that ranks as the leading cause of irreversible blindness. The Company's flagship product, miLens, is an innovative, non-invasive, contact lens-based device capable of monitoring intraocular pressure—the primary and only treatable risk factor for glaucoma. This addresses a significant unmet need that has persisted since the 1950s. Strong clinical results for miLens were presented at the American Glaucoma Society 2023 meeting. The Company plans to commercialize miLens in 2024. miLens utilizes a unique, electronics-free sensor technology owned by Smartlens and protected by a portfolio of patents spanning more than 40 countries. Additionally, Smartlens owns THERmic, an advanced non-invasive drug delivery technology that helps prevent disease progression, enhances treatment effectiveness by offering personalized therapies for individual patients. It also lays the foundation for a new generation of therapies. Smartlens has received investments from prominent institutions, venture capital firms, Stanford University, and key opinion leaders. In recognition of its accomplishments, Smartlens was honored with the "Outstanding Innovation in Medical Technology and Life Sciences" award at the 2021 High-Tech Awards by Octane. The company’s technologies have also been recognized by reputable sources such as Nature Medicine, Fortune, BBC, and ABC News. Smartlens envisions a world where Glaucoma can no longer rob people of their vision and quality of life.